US ITC Launches Section 337 Investigation on Photon-Counting CT Detector Modules

On May 27, 2026, the U.S. International Trade Commission (ITC) initiated investigation No. 337-TA-2155 concerning cadmium telluride (CdTe) and cadmium zinc telluride (CZT) detector modules used in photon-counting computed tomography (CT) systems. The investigation targets multiple Chinese exporters and alleges infringement of three core patents held by Varex Imaging Corporation (e.g., US11223789B2). This action is highly relevant to medical imaging device manufacturers, component suppliers, export compliance officers, and global supply chain managers — particularly those engaged in high-end diagnostic imaging hardware.

Event Overview

On May 27, 2026, the U.S. International Trade Commission formally instituted investigation No. 337-TA-2155. The complaint centers on CdTe/CZT-based detector modules designed for photon-counting CT systems, imported into the United States by several Chinese entities. The complainant, Varex Imaging Corporation, asserts that these modules infringe U.S. Patent Nos. US11223789B2, and two additional patents not publicly named in the initial notice. If a violation is found, the ITC may issue a general exclusion order (GEO), barring importation of infringing products regardless of source.

Industries Affected by Segment

Direct Exporters and OEMs

Companies exporting CdTe/CZT detector modules from China to the U.S. face immediate customs risk and potential shipment detention. A GEO would prohibit entry of any such module — even if manufactured outside China but incorporating components sourced from respondents — thereby disrupting existing commercial contracts and delivery commitments.

Photon-Counting CT System Integrators

Original equipment manufacturers assembling full photon-counting CT scanners may encounter supply chain interruptions if their detector modules fall under the scope of the investigation. Since CdTe/CZT detectors are currently among the few commercially viable sensor technologies for clinical photon-counting CT, alternatives are limited in performance and availability.

Materials and Subcomponent Suppliers

Vendors supplying CdTe or CZT crystals, readout ASICs, or hybridization services to module assemblers may see reduced order volumes or delayed qualification cycles. While not directly named in the complaint, downstream dependency means demand volatility can propagate upstream quickly.

Regulatory and Compliance Service Providers

Firms offering ITC litigation support, patent landscape analysis, or export control advisory services are likely to see increased client inquiries related to Section 337 defense strategy, design-around assessment, and import classification verification for detector-related goods.

What Stakeholders Should Monitor and Do Now

Track official filings and procedural deadlines

The ITC docket will publish key documents including the Notice of Investigation, Initial Determination timelines, and respondent submissions. Parties should monitor the ITC’s Electronic Document Information System (EDIS) for updates — especially the deadline for filing responses (typically 20 days after institution).

Identify whether specific product SKUs or technical configurations fall within claim scope

Analysis shows that the asserted patents relate to pixelated detector architecture, charge-sharing correction methods, and interconnect designs. Companies should conduct preliminary claim charting against their own module specifications — focusing on signal processing pathways and physical layout — rather than relying solely on material composition (e.g., CdTe vs. CZT).

Distinguish between policy signals and enforceable outcomes

Observably, this investigation reflects growing enforcement attention on high-value medical imaging components, but no determination has been made. A GEO remains contingent on findings of violation and domestic industry requirement satisfaction. Stakeholders should avoid premature operational changes based solely on the institution notice.

Prepare contingency plans for sourcing and documentation

Current more appropriate actions include reviewing bills of materials for traceability, validating origin declarations, and initiating internal discussions with legal counsel regarding potential design-arounds or licensing feasibility — especially if modules are already deployed in FDA-cleared systems subject to ongoing quality system regulation.

Editorial Perspective / Industry Observation

This investigation is better understood as an early-stage regulatory signal than an imminent trade barrier. Analysis shows that while Section 337 investigations carry significant weight, over 40% of such cases settle or terminate before final determination. From an industry perspective, it highlights increasing strategic use of IP enforcement in capital-intensive medtech subsegments where technical differentiation is narrow and lead times for alternative solutions are long. It also underscores how patent assertions targeting foundational components — rather than end-user devices — can ripple across multi-tiered global supply chains. Continued monitoring is warranted, particularly for developments around domestic industry standing and potential parallel proceedings at the U.S. Patent and Trademark Office (USPTO).

In summary, the ITC’s initiation of investigation 337-TA-2155 represents a targeted escalation in IP enforcement within advanced medical imaging hardware. Its significance lies less in immediate trade restriction and more in its implications for supply chain resilience, export compliance rigor, and long-term technology sourcing strategy. At this stage, it is more appropriately interpreted as a procedural milestone requiring measured assessment — not a definitive market access restriction.

Source: U.S. International Trade Commission (ITC) Official Notice of Investigation No. 337-TA-2155, issued May 27, 2026.
Note: Patent numbers and respondent identities remain subject to confirmation in subsequent ITC filings; further developments — including potential settlement, motion practice, or remedial orders — require ongoing observation.